Last reviewed · How we verify

Prednisone+Cytarabine+vincristine

Shanghai Children's Medical Center · Phase 3 active Small molecule

Prednisone+Cytarabine+vincristine is a Combination chemotherapy regimen with corticosteroid Small molecule drug developed by Shanghai Children's Medical Center. It is currently in Phase 3 development for Acute lymphoblastic leukemia (ALL) in pediatric patients, Acute myeloid leukemia (AML) in pediatric patients.

This combination uses a corticosteroid to suppress immune responses and two chemotherapy agents to kill rapidly dividing cancer cells through different mechanisms.

This combination uses a corticosteroid to suppress immune responses and two chemotherapy agents to kill rapidly dividing cancer cells through different mechanisms. Used for Acute lymphoblastic leukemia (ALL) in pediatric patients, Acute myeloid leukemia (AML) in pediatric patients.

At a glance

Generic namePrednisone+Cytarabine+vincristine
SponsorShanghai Children's Medical Center
Drug classCombination chemotherapy regimen with corticosteroid
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Prednisone is a corticosteroid that reduces inflammation and suppresses immune function. Cytarabine is a cytidine analog that inhibits DNA synthesis and is incorporated into DNA, causing cell death in rapidly dividing cells. Vincristine is a vinca alkaloid that binds to tubulin and disrupts microtubule formation, arresting cells in metaphase. Together, this regimen targets leukemic blasts through multiple mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Prednisone+Cytarabine+vincristine

What is Prednisone+Cytarabine+vincristine?

Prednisone+Cytarabine+vincristine is a Combination chemotherapy regimen with corticosteroid drug developed by Shanghai Children's Medical Center, indicated for Acute lymphoblastic leukemia (ALL) in pediatric patients, Acute myeloid leukemia (AML) in pediatric patients.

How does Prednisone+Cytarabine+vincristine work?

This combination uses a corticosteroid to suppress immune responses and two chemotherapy agents to kill rapidly dividing cancer cells through different mechanisms.

What is Prednisone+Cytarabine+vincristine used for?

Prednisone+Cytarabine+vincristine is indicated for Acute lymphoblastic leukemia (ALL) in pediatric patients, Acute myeloid leukemia (AML) in pediatric patients.

Who makes Prednisone+Cytarabine+vincristine?

Prednisone+Cytarabine+vincristine is developed by Shanghai Children's Medical Center (see full Shanghai Children's Medical Center pipeline at /company/shanghai-children-s-medical-center).

What drug class is Prednisone+Cytarabine+vincristine in?

Prednisone+Cytarabine+vincristine belongs to the Combination chemotherapy regimen with corticosteroid class. See all Combination chemotherapy regimen with corticosteroid drugs at /class/combination-chemotherapy-regimen-with-corticosteroid.

What development phase is Prednisone+Cytarabine+vincristine in?

Prednisone+Cytarabine+vincristine is in Phase 3.

What are the side effects of Prednisone+Cytarabine+vincristine?

Common side effects of Prednisone+Cytarabine+vincristine include Myelosuppression (neutropenia, thrombocytopenia, anemia), Infection, Nausea and vomiting, Mucositis, Peripheral neuropathy, Hyperglycemia.

Related